In Re: Denture Cream Products Liability Litigation

CourtDistrict Court, District of Columbia
DecidedJuly 3, 2013
DocketMisc. No. 2013-0384
StatusPublished

This text of In Re: Denture Cream Products Liability Litigation (In Re: Denture Cream Products Liability Litigation) is published on Counsel Stack Legal Research, covering District Court, District of Columbia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re: Denture Cream Products Liability Litigation, (D.D.C. 2013).

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA __________________________________________ ) In re: ) ) DENTURE CREAM PRODUCTS ) Miscellaneous Action No. 13-384 LIABILITY LITIGATION ) (RBW) ) ) ) __________________________________________)

MEMORANDUM OPINION

The Procter & Gamble Distributing LLC, The Procter & Gamble Manufacturing

Company, and The Procter & Gamble Company (collectively, “Procter & Gamble”) are

defendants in a multidistrict litigation pending in the United States District Court for the

Southern District of Florida, In re Denture Cream Products Liability Litigation, Civ. No. 09-2051

(S.D. Fla.). Currently before this Court is Procter & Gamble’s Motion to Compel the Production

of Documents from Sarfez Pharmaceuticals, Inc. and Sarfez USA, Inc. and Memorandum of Law

in Support (“Defs.’ Mem.”). After carefully considering the parties’ submissions, 1 the Court

concludes for the following reasons that it must grant the defendants’ motion.

I. BACKGROUND

The plaintiffs in the In re Denture Cream Products Liability Litigation multidistrict

litigation “allege that excessive use of the denture cream product, Fixodent, blocks copper

absorption and ultimately leads to neurological injury.” Defs.’ Mem. at 2. In connection with

the prosecution of their case, the plaintiffs paid third parties Dr. Salim Shah and his companies,

1 In addition to those filings already identified, the Court considered the following submissions by the parties in reaching its decision: Respondents’ Opposition to Petitioners’ Procter & Gamble Distributing LLC, Procter & Gamble Manufacturing Company and Procter & Gamble Company’s Motion to Compel (“Resp’ts’ Opp’n”); and the defendants’ Reply in Support of Procter & Gamble’s Motion to Compel the Production of Documents from Sarfez Pharmaceuticals, Inc. and Sarfez USA, Inc. (“Defs.’ Reply”).

1 Sarfez Pharmaceuticals, Inc. and Sarfez USA, Inc. (collectively, the “Sarfez Entities”) “over

$300,000 to perform a study in India,” known as the Zinc/077/12 Study. Id. at 2; id., Exhibit

(“Ex.”) B (November 26, 2012 Declaration of Dr. Salim Shah, Esq. (“2012 Shah Decl.”)) ¶ 4

(“Sarfez Pharmaceuticals is responsible for implementing [the] [Z]inc/077/12 [S]tudy that is

being conducted in India.”)). The Study is intended “to determine how much copper, if any, is

blocked, during exposure to Fixodent.” Id., Ex. B (2012 Shah Decl.) ¶ 4. According to Dr.

Shah, the Study was to be completed and its results delivered by December 28, 2012, to Dr.

Frederick K. Askari, who designed the Study. Id., Ex. B (2012 Shah Decl.) ¶¶ 4, 13.

The defendants “initially sought discovery regarding the Zinc/077/12 Study from [the]

Plaintiffs, propounding document requests and interrogatories on [the] Plaintiffs on December

10, 2012.” Defs.’ Mem. at 3. The plaintiffs, however, represented that they did not have all of

the documents relating to the Study, and responded that the requests were “more appropriately

directed to Sarfez Pharmaceuticals.” Id. at 3-4; id., Ex. D (Plaintiffs’ Responses and Objections

to Defendants The Procter & Gamble Distributing, LLC and The Procter & Gamble

Manufacturing Co. Requests for Production Re Zinc/077/12 Study) at 5, 8-12, 14-16, 19-22, 25-

31.

The defendants therefore sought the Zinc/077/12 Study, its underlying raw data, and

other related materials from the Sarfez Entities. Defs.’ Mem. at 4; id., Ex. G (February 1, 2013

Subpoenas). The Sarfez Entities do not deny, see generally Resp’ts’ Opp’n, that they “served no

objections or responses to the Sarfez Subpoenas, nor did they produce a privilege log,” Defs.’

Mem. at 4. Instead, over the next two and a half months, the Sarfez Entities “produced in excess

of 1500 pages of responsive discovery material,” Resp’ts’ Opp’n at 3, but the defendants contend

that the Sarfez Entities “failed to produce numerous responsive documents,” Defs.’ Mem. at 5.

2 The Sarfez Entities reply that they have been “cooperative at every request . . . and ha[ve]

produced all documents within [their] possession and control.” Resp’ts’ Opp’n at 3.

The defendants have now moved to compel the Sarfez Entities to: “(i) produce all

responsive documents; (ii) produce their computers for forensic imaging; and (iii) reimburse

Procter & Gamble for the fees and costs incurred in connection with the Motion.” Defs.’ Mem.

at 13-14.

II. STANDARD OF REVIEW

A court from which a subpoena issues pursuant to Federal Rule of Civil Procedure 45 has

the power to compel the production of documents from a nonparty witness. See In re Sealed

Case, 141 F.3d 337, 341 (D.C. Cir. 1998). In considering a motion to compel the production of

discovery, Rule 45 “‘requires that district courts quash subpoenas that call for privileged matter

or would cause an undue burden.’” In re Micron Tech., Inc. Sec. Litig., 264 F.R.D. 7, 9 (D.D.C.

2010) (quoting Watts v. SEC, 482 F.3d 501, 508 (D.C. Cir. 2007)). “The burden lies on the

party resisting discovery to show that the documents requested are either unduly burdensome or

privileged.” Id.; Fed. R. Civ. P. 45(d)(1)(D); see also Millennium TGA, Inc. v. Comcast Cable

Commc’ns LLC, 286 F.R.D. 8, 11 (D.D.C. 2012) (“The person objecting to production has a

heavy burden to show that the subpoena should not be enforced.” (citing Northrop Corp. v.

McDonnell Douglas Corp., 751 F.2d 395, 403 (D.C. Cir. 1984)).

When deciding a motion to compel, a court must consider first whether the discovery

sought is relevant. Discovery obtained from a nonparty pursuant to Rule 45 has “the same scope

as provided in Rule 26(b), thus promoting uniformity.” Advisory Committee Note to 1946

Amendment to Rule 45(d). In general, under Rule 26(b), “[p]arties may obtain discovery

regarding any nonprivileged matter that is relevant to any party’s claim or defense.” Fed. R. Civ.

3 P. 26(b)(1). For purposes of discovery, relevance is liberally construed. Burlington Ins. Co. v.

Okie Dokie, Inc., 368 F. Supp. 2d 83, 86 (D.D.C. 2005) (citing Rule 26(b)(1)); Food Lion, Inc. v.

United Food & Comm’l Working Int’l Union, 103 F.3d 1007, 1012 (D.C. Cir. 1997)). Thus,

“[t]he term relevance at the discovery stage is broadly interpreted to include information which is

not admissible at the trial if the discovery appears to be reasonably calculated to lead to the

discovery of admissible evidence.” Covertino v. DOJ, 565 F. Supp. 2d 10, 12 (D.D.C. 2008).

Therefore, with respect to a Rule 45 subpoena, “‘[a] request for discovery should be considered

relevant if there is any possibility that the information sought may be relevant to the claim or

defense of any party.’” Hesco Bastion Ltd. v. Greenberg Traurig LLP, No. 09-0357, 2009 WL

Free access — add to your briefcase to read the full text and ask questions with AI

Related

McCurdy Group, LLC v. American Biomedical Group, Inc.
9 F. App'x 822 (Tenth Circuit, 2001)
In Re: Sealed Case
141 F.3d 337 (D.C. Circuit, 1998)
Watts v. Securities & Exchange Commission
482 F.3d 501 (D.C. Circuit, 2007)
Convertino v. United States Department of Justice
565 F. Supp. 2d 10 (District of Columbia, 2008)
Walker v. CENTER FOR FOOD SAFETY
667 F. Supp. 2d 133 (District of Columbia, 2009)
Burlington Insurance v. Okie Dokie, Inc.
368 F. Supp. 2d 83 (District of Columbia, 2005)
Barnes v. District of Columbia
289 F.R.D. 1 (District of Columbia, 2012)
Millennium Tga, Inc. v. Comcast Cable Communications LLC
286 F.R.D. 8 (District of Columbia, 2012)
In Re MICRON TECHNOLOGY, INC. SECURITIES LITIGATION
264 F.R.D. 7 (District of Columbia, 2010)
Alexander v. Federal Bureau of Investigation
186 F.R.D. 21 (District of Columbia, 1998)
Alexander v. Federal Bureau of Investigation
192 F.R.D. 37 (District of Columbia, 2000)
Simon Property Group L.P. v. mySimon, Inc.
194 F.R.D. 639 (S.D. Indiana, 2000)
Huthnance v. District of Columbia
255 F.R.D. 285 (District of Columbia, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
In Re: Denture Cream Products Liability Litigation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-denture-cream-products-liability-litigation-dcd-2013.